Table 1.
Patients’ characteristics
| Group < 15% | Group > 15% | All patients | ARO 96-02 [3] | |
|---|---|---|---|---|
| Number of patients | 45 | 40 | 85 | 148 |
| Age at radiotherapy—mean | 63 | 65 | 64 | 65 |
| iPSA—mean | 8.88 ng/ml | 9.02 ng/ml | 8.94 ng/ml | 9.7 ng/ml |
| < 10 ng/ml | 38 (84%) | 13 (32%) | 51 (60%) | n.a. |
| 10–20 ng/ml | 7 (16%) | 20 (50%) | 27 (32%) | n.a. |
| > 20 ng/ml | – | 7 (18%) | 7 (8%) | n.a. |
| Gleason score | ||||
| 6 | 28 (62%) | 2 (5%) | 30 (35%) | 38% |
| 7 | 17 (38%) | 26 (65%) | 43 (51%) | 50% |
| 8–10 | – | 12 (30%) | 12 (14%) | 12% |
| Pathological tumour stage | ||||
| pT2c | 21 (47%) | 11 (27.5%) | 32 (38%) | 3% |
| pT3 | 19 (42%) | 26 (65%) | 45 (53%) | 94% |
| pT4 | 5 (11%) | 3 (7.5%) | 8 (9%) | 3% |
| Positive resection margins | 42 (93%) | 39 (97.5%) | 81 (95%) | 68% |
| Lymphadenectomy performed | 13 (29%) | 17 (42.5%) | 30 (35%) | 100% |
|
Numbers of LN removed—mean (min-max) |
5 (2–10) |
9 (2–44) |
7 (2–44) |
n.a. |
|
PSA postoperative ng/ml—mean (min-max) |
0.02 (0–0.1) |
0.02 (0–0.1) |
0.02 (0–0.1) |
< 0.1 100% |
|
PSA prior RT ng/ml—mean (min-max) |
0.02 (0–0.1) |
0.03 (0–0.1) |
0.02 (0–0.1) |
< 0.1 100% < 0.05 80% |
| Time RPE to RT in months—median | 3 | 4 | 4 | 3.5 |
|
Local Radiation dose Gy—mean (min-max) |
66.4 Gy (60–72 Gy) |
66.2 Gy (66–72 Gy) |
66.3 Gy (60–72 Gy) |
60 Gy |
|
Follow-up in months—median (min-max) |
72 (12–174) |
54 (1–197) |
60 (1–197) |
54 |
| 5 year bNED rate | 97% | 77% | 88% | 72% |
iPSA initial prostate specific antigen, LN lymph nodes, RT radiotherapy, RPE radical prostatectomy